<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prior to the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, <z:chebi fb="105" ids="17234">glucose</z:chebi> levels increase into the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic states</z:e> of isolated impaired fasting glycaemia (i-IFG), isolated <z:hpo ids='HP_0000833'>impaired glucose tolerance</z:hpo> (i-IGT), or combined IFG/IGT </plain></SENT>
<SENT sid="1" pm="."><plain>A better understanding of the aetiology and pathophysiology of the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic states</z:e> might give a basis for the development of individualised prevention and treatment strategies for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Several studies have examined mechanisms and potential aetiological factors leading to the development of the different <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic states</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The pathophysiology of i-IFG seems to include the following key defects: reduced hepatic insulin sensitivity, stationary <z:hpo ids='HP_0006279'>beta cell dysfunction</z:hpo> and/or <z:hpo ids='HP_0011010'>chronic</z:hpo> low beta cell mass, altered glucagon-like <z:chebi fb="7" ids="16670">peptide</z:chebi>-1 secretion and inappropriately <z:mp ids='MP_0002710'>elevated glucagon secretion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>Conversely, the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic state</z:e> i-IGT is characterised by reduced peripheral insulin sensitivity, near-<z:mpath ids='MPATH_458'>normal</z:mpath> hepatic insulin sensitivity, progressive loss of beta cell function, reduced secretion of <z:chebi fb="105" ids="17234">glucose</z:chebi>-dependent insulinotropic <z:chebi fb="1" ids="15841">polypeptide</z:chebi> and inappropriately <z:mp ids='MP_0002710'>elevated glucagon secretion</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Individuals developing combined IFG/IGT exhibit severe defects in both peripheral and hepatic insulin sensitivity as well as a progressive loss of beta cell function </plain></SENT>
<SENT sid="6" pm="."><plain>The aetiologies of i-IFG and i-IGT also seem to differ, with i-IFG being predominantly related to genetic factors, smoking and male sex, while i-IGT is predominantly related to physical inactivity, unhealthy diet and <z:hpo ids='HP_0004322'>short stature</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Since the transition from the <z:e sem="disease" ids="C0362046" disease_type="Disease or Syndrome" abbrv="">prediabetic states</z:e> to overt type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is characterised by a non-reversible vicious cycle that includes severe deleterious effects on <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, there are good reasons to use the well-established aetiological and pathophysiological differences in i-IFG, i-IGT and IFG/IGT to design individualised preventive strategies </plain></SENT>
</text></document>